canine osteoarthritis
Recently Published Documents


TOTAL DOCUMENTS

116
(FIVE YEARS 31)

H-INDEX

21
(FIVE YEARS 3)

2021 ◽  
Vol 26 (11) ◽  
pp. 248-254
Author(s):  
Robyn Lowe

Owners often reach for over-the-counter supplements for the management of canine osteoarthritis, believing them to be natural, side effect-free options. Some may ask for your opinion as a veterinary professional, whereas others will come to you already using certain products. It is imperative to be aware of the evidence for the relevant products and to encourage the use of good quality products as the first option. The aim should be to help prevent owners of arthritic dogs wasting their money buying multiple products with little or no evidence to back up their use, to be wary of bold unsubstantiated claims for improvements or health benefits, and to ensure that supplements are not used as a sole intervention for the management of arthritic pain, as they are unlikely to have the evidence base to support this claim.


2021 ◽  
Vol 2 ◽  
pp. 31-38
Author(s):  
Marti Drum ◽  
Emily McKay ◽  
David Levine ◽  
Denis J. Marcellin-Little

2021 ◽  
Vol 26 (6) ◽  
pp. 73-80
Author(s):  
Hannah Capon

Canine osteoarthritis was recently reclassified as a welfare concern by the Veterinary Companion Animal Surveillance System (VetCompass), an initiative run by the Royal College of Veterinary Surgeons, focused on improving companion animal health. This condition is a common cause for consultation in first opinion practice, with an estimated 35% of the canine population being affected. Chronic pain is complex and a multimodal approach is best for management, which includes pharmaceuticals employed in a methodical manner. This article provides an overview of the types of pain associated with canine osteoarthritis, as well as how to recognise them. Making reference to hypothetical cases, the appropriate pharmaceutical management is described. Further management strategies, as part of a multimodal approach, are summarised to ensure best practice.


PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0252279
Author(s):  
Chiara Caterino ◽  
Federica Aragosa ◽  
Giovanni Della Valle ◽  
Dario Costanza ◽  
Francesco Lamagna ◽  
...  

Introduction Osteoarthritis is a progressive degenerative joint disease which is high prevalent in dogs. In the late stage of the disease, it determines chronic neuropathic pain which leads to reduced quality-of-life in affected patients. To date it has not yet been identified a specific treatment, but it has been proved that nutraceutical and dietary supplements may play an important role in controlling inflammation and pain. The aim of this study was to evaluate, by the use of force plate gait analysis, the clinical efficacy of Boswellia and Curcuvet® combined with conventional nutraceutical therapy compared with conventional nutraceutical alone in dogs affected by osteoarthritis. Materials and methods Twenty client-owned dogs, over 12 months old and 20 kg of body-weight, with a confirmed diagnosis of Osteoarthritis, were included in this randomized, double-blinded study. The dogs were randomly divided into two groups: the first group (A) received a conventional nutraceutical (consisted in a preparation of glucosamine, chondroitin sulfate, fish-oil containing 80% of omega 3-fatty acid, vitamin C and E, saccharomyces Cerevisiae) with a combination of acid boswellic and Curcuvet®, while the second group (B) received a conventional nutraceutical. All the enrolled dogs underwent a washout period before starting the treatment with nutraceuticals products which were the only admitted treatment over the study period. A full orthopaedic and neurologic examination, and force plate gait analysis were performed before starting the treatment, at 45, 90, and 60 days post-treatment. Ground reaction forces were recorded and analyzed. Results Twenty dogs were enrolled in the study. In both groups there was an increasing values of ground reaction forces. These results might indicate that both nutraceutical products determined a better condition in terms of pain feeling but that effect is much more visible after 60 days from the end of the administration in treated group. Discussion In conclusion Curcuvet in combination with Boswellic acid could be considered a valid aid in a multimodal treatment for canine osteoarthritis.


2021 ◽  
Vol 8 ◽  
Author(s):  
Carlien Brondeel ◽  
Glenn Pauwelyn ◽  
Evelien de Bakker ◽  
Jimmy Saunders ◽  
Yves Samoy ◽  
...  

Osteoarthritis (OA) is currently an incurable and progressive condition in dogs causing chronic joint pain and possibly increasing disability. Due to the poor healing capacity of cartilage lesions that occur with OA, development of effective therapeutics is difficult. For this reason, current OA therapy is mostly limited to the management of pain and inflammation, but not directed ad disease modification. In the search for a safe and effective OA treatment, mesenchymal stem cells (MSCs) have been of great interest since these cells might be able to restore cartilage defects. The designs of OA studies on MSC usage, however, are not always consistent and complete, which limits a clear evaluation of MSC efficacy. The general study results show a tendency to improve lameness, joint pain and range of motion in dogs suffering from naturally-occurring OA. Assessment of the cartilage surface demonstrated the ability of MSCs to promote cartilage-like tissue formation in artificially created cartilage defects. Immunomodulatory capacities of MSCs also seem to play an important role in reducing pain and inflammation in dogs. It should be mentioned, however, that in the current studies in literature there are specific design limitations and further research is warranted to confirm these findings.


2021 ◽  
Vol 57 (2) ◽  
pp. 81-90
Author(s):  
Sebastian Mejia ◽  
Felix Michael Duerr ◽  
Gregg Griffenhagen ◽  
Stephanie McGrath

ABSTRACT The objective of this study was to provide preliminary data describing the safety and effect of cannabidiol (CBD) for symptom relief of canine osteoarthritis-associated pain in a clinical setting using objective outcome measures. Twenty-three client-owned dogs with naturally occurring osteoarthritis of appendicular joints completed this prospective, double-blinded, crossover, placebo-controlled study. Baseline data were acquired for 4 wk, followed by random allocation to either placebo or CBD treatment for 6 wk, followed by 6 wk with the opposite treatment. Outcome measures included objective gait analysis, activity counts (via accelerometry) and clinical metrology instruments. There were no differences noted between groups at any time point for any of the recorded outcome measures. Adverse events associated with CBD administration included elevation in liver enzymes (n = 14) and vomiting (n = 2).


Sign in / Sign up

Export Citation Format

Share Document